Celltrion Begins US Phase III For Infliximab SC, Aims For 2022 Launch

 
• By Jung Won Shin
  
Celltrion researcher
Celltrion Takes New Drug Approval Pathway For Remsima SC • Source: Celltrion Inc.

More from Clinical Trials

More from R&D